Fixed-Ratio Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Treatment in Type 2 Diabetic (T2DM) Patients with Diabetic Foot Ulcers (DFU) and Critical Limb Ischemia (CLI)

被引：0

作者：

Falcetta, Pierpaolo

Indovina, Francesco S.

Giannarelli, Rosa

Piaggesi, Alberto

Penno, Giuseppe

Miccoli, Roberto

Del Prato, Stefano

Coppelli, Alberto

机构：

来源：

DIABETES | 2019年 / 68卷

关键词：

D O I：

10.2337/db19-2256-PUB

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2256-PUB

引用

页数：2

共 33 条

[21] Assessment of treatment satisfaction in long-acting insulin analogues: Evidence from a basal-bolus regimen treating type 1 diabetic patients with insulin detemir vs. insulin glargine
Brod, Meryl
Lammert, Morten
DIABETES, 2006, 55 : A558 - A558
[22] Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
Tabak, Adam G.
Anderson, John
Aschner, Pablo
Liu, Minzhi
Saremi, Aramesh
Stella, Peter
Tinahones, Francisco J.
Wysham, Carol
Meier, Juris J.
DIABETES THERAPY, 2020, 11 (01) : 305 - 318
[23] Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
Ádám G. Tabák
John Anderson
Pablo Aschner
Minzhi Liu
Aramesh Saremi
Peter Stella
Francisco J. Tinahones
Carol Wysham
Juris J. Meier
Diabetes Therapy, 2020, 11 : 305 - 318
[24] iGlarLixi Fixed-Ratio Combination vs. Insulin Glargine and Lixisenatide in Patients with T2DM Treated Previously with Two Oral Antidiabetics: LixiLan-O Subgroup Analysis
Russell-Jones, David
Mccrimmon, Rory J.
Barber, Thomas M.
Baradez, Cecile
Baxter, Michael A.
Davies, Melanie
DIABETES, 2017, 66 : LB35 - LB35
[25] PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-COM STUDY
Moock, J.
Hessel, F.
Kohlmann, T.
VALUE IN HEALTH, 2009, 12 (07) : A411 - A411
[26] Superior Effects with Combination of Insulin Degludec (IDeg) and Liraglutide (Lira) (IDeg plus Lira) Compared with Basal-Bolus Insulin Therapy (BB) in Hemodialysis (HD) Patients with Poorly Controlled Type 2 Diabetes (T2D): An Assessment by Continuous Glucose
Funakoshi, Satoshi
Hashiguchi, Jyunichiro
Etoh, Rica
Ikeda, Kouhei
Harada, Takashi
Utsunomiya, Kazunori
Mori, Yutaka
DIABETES, 2015, 64 : A45 - A45
[27] Durability of Combination Therapy with Exenatide and Pioglitazone vs. Basal Bolus Insulin in Poorly Controlled T2DM Patients-Three-Year Follow-Up of the QATAR Study
Abdul-Ghani, Muhammad
Migahid, Osama, Sr.
Megahed, Ayman, Sr.
Mohammad, Mohammad Fawaz.
Defronzo, Ralph A.
Jayyousi, Amin
DIABETES, 2018, 67
[28] In Insulin-Naive Patients with T2DM Uncontrolled on GLP-1 Receptor Agonists (GLP-1RA), IDegLira (Novel Combination of Insulin Degludec plus Liraglutide) Resulted in Improved Patient-Reported Outcomes vs. Unchanged GLP-1RA
Linjawi, Sultan
Brod, Meryl
Bode, Bruce W.
Chaykin, Louis B.
Courreges, Jeanpierre
Handelsman, Yehuda
Kongso, Jens Harald
Reiter, PanagIota Diamantopoulou
Simpson, Richard W.
DIABETES, 2015, 64 : A296 - A296
[29] More Satisfied, But Why? A Pooled Analysis of Treatment Satisfaction Following the Initiation of Insulin Glargine vs. Comparators in Insulin-Naive Patients With Type 2 Diabetes Mellitus (T2DM)
Polonsky, William H.
Traylor, Louise
Wei, Wenhui
Shi, Rebecca
Ameer, Barbara
Vlajnic, Aleksandra
Nicolucci, Antonio
DIABETES, 2012, 61 : A202 - A202
[30] Improved Glucose Control without Increased Hypoglycemia Risk at Any Level of HbA1c Reduction with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (LixiLan) vs. Insulin Glargine Alone Both Added On to Metformin in Type 2 Diabetes (T2DM)
Rosenstock, Julio
Guerci, Bruno
Paranjape, Sachin
Berria, Rachele
Souhami, Elisabeth
Aroda, Vanita
DIABETES, 2015, 64 : A44 - A45

← 1 2 3 4 →